NDC 58411-657

SHISEIDO FUTURE Solution LX INFINITE TREATMENT PRIMER

Titanium Dioxide, Octinoxate, And Ensulizole

SHISEIDO FUTURE Solution LX INFINITE TREATMENT PRIMER is a Topical Emulsion in the Human Otc Drug category. It is labeled and distributed by Shiseido Americas Corporation. The primary component is Titanium Dioxide; Octinoxate; Ensulizole.

Product ID58411-657_5372d970-e30f-48ff-b10f-2b2f74dfccc9
NDC58411-657
Product TypeHuman Otc Drug
Proprietary NameSHISEIDO FUTURE Solution LX INFINITE TREATMENT PRIMER
Generic NameTitanium Dioxide, Octinoxate, And Ensulizole
Dosage FormEmulsion
Route of AdministrationTOPICAL
Marketing Start Date2021-05-01
Marketing CategoryOTC MONOGRAPH NOT FINAL /
Application Numberpart352
Labeler NameSHISEIDO AMERICAS CORPORATION
Substance NameTITANIUM DIOXIDE; OCTINOXATE; ENSULIZOLE
Active Ingredient Strength2 g/40mL; g/40mL; g/40mL
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 58411-657-10

1 TUBE in 1 CARTON (58411-657-10) > 40 mL in 1 TUBE
Marketing Start Date2021-05-01
NDC Exclude FlagN
Sample Package?N

Drug Details


© 2021 FDA.report
This site is not affiliated with or endorsed by the FDA.